373 related articles for article (PubMed ID: 17287412)
1. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men.
Shimon I; Benbassat C; Hadani M
Eur J Endocrinol; 2007 Feb; 156(2):225-31. PubMed ID: 17287412
[TBL] [Abstract][Full Text] [Related]
2. Giant prolactinomas in men: efficacy of cabergoline treatment.
Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
[TBL] [Abstract][Full Text] [Related]
3. Giant prolactinoma and effectiveness of medical management.
Acharya SV; Gopal RA; Menon PS; Bandgar TR; Shah NS
Endocr Pract; 2010; 16(1):42-6. PubMed ID: 19703803
[TBL] [Abstract][Full Text] [Related]
4. Rapid improvement in visual loss with cabergoline treatment in a giant prolactinoma case: 5 years survey.
Tasan E; Hanimoglu H; Turgut S; Ilhan MM; Evran S; Kaynar MY
Neuro Endocrinol Lett; 2015; 36(1):28-30. PubMed ID: 25789596
[TBL] [Abstract][Full Text] [Related]
5. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
[TBL] [Abstract][Full Text] [Related]
6. Brain and optic chiasmal herniation following cabergoline treatment for a giant prolactinoma: wait or intervene?
Papanastasiou L; Fountoulakis S; Pappa T; Liberopoulos K; Malliopoulos D; Markou A; Piaditis G
Hormones (Athens); 2014; 13(2):290-5. PubMed ID: 24776630
[TBL] [Abstract][Full Text] [Related]
7. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
[TBL] [Abstract][Full Text] [Related]
8. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
Shimon I; Sosa E; Mendoza V; Greenman Y; Tirosh A; Espinosa E; Popovic V; Glezer A; Bronstein MD; Mercado M
Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
[TBL] [Abstract][Full Text] [Related]
9. Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
Ferrari CI; Abs R; Bevan JS; Brabant G; Ciccarelli E; Motta T; Mucci M; Muratori M; Musatti L; Verbessem G; Scanlon MF
Clin Endocrinol (Oxf); 1997 Apr; 46(4):409-13. PubMed ID: 9196602
[TBL] [Abstract][Full Text] [Related]
10. Cabergoline as a first-line treatment in newly diagnosed macroprolactinomas.
Pontikides N; Krassas GE; Nikopoulou E; Kaltsas T
Pituitary; 2000 May; 2(4):277-81. PubMed ID: 11081149
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients.
Ono M; Miki N; Kawamata T; Makino R; Amano K; Seki T; Kubo O; Hori T; Takano K
J Clin Endocrinol Metab; 2008 Dec; 93(12):4721-7. PubMed ID: 18812485
[TBL] [Abstract][Full Text] [Related]
12. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma?
Phillips J; East HE; French SE; Melcescu E; Hamilton RD; Nicholas WC; Fratkin JF; Parent AD; Luzardo G; Koch CA
Hormones (Athens); 2012; 11(4):477-82. PubMed ID: 23422771
[TBL] [Abstract][Full Text] [Related]
13. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients.
Vroonen L; Jaffrain-Rea ML; Petrossians P; Tamagno G; Chanson P; Vilar L; Borson-Chazot F; Naves LA; Brue T; Gatta B; Delemer B; Ciccarelli E; Beck-Peccoz P; Caron P; Daly AF; Beckers A
Eur J Endocrinol; 2012 Nov; 167(5):651-62. PubMed ID: 22918301
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma.
Cho EH; Lee SA; Chung JY; Koh EH; Cho YH; Kim JH; Kim CJ; Kim MS
J Korean Med Sci; 2009 Oct; 24(5):874-8. PubMed ID: 19794986
[TBL] [Abstract][Full Text] [Related]
15. Evaluaton of therapy with cabergoline in men with macroprolactinoa.
Andrysiak-Mamos E; Kaźmierczyk-Puchalska A; Zochowska E; Sowińska-Przepiera E; Sagan L; Kojder I; Syrenicz A
Pomeranian J Life Sci; 2015; 61(3):263-9. PubMed ID: 27344867
[TBL] [Abstract][Full Text] [Related]
16. Dopamine agonist for the rapid improvement of visual field defects in giant and macro-prolactinomas.
Hacisahinogullari H; Canturk S; Dogansen S; Yarman S
J Fr Ophtalmol; 2022 May; 45(5):511-518. PubMed ID: 35272874
[TBL] [Abstract][Full Text] [Related]
17. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma.
Cannavò S; Curtò L; Squadrito S; Almoto B; Vieni A; Trimarchi F
J Endocrinol Invest; 1999 May; 22(5):354-9. PubMed ID: 10401709
[TBL] [Abstract][Full Text] [Related]
18. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
Iyer P; Molitch ME
Endocr Pract; 2011; 17(3):e55-8. PubMed ID: 21324816
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas.
Bhansali A; Walia R; Dutta P; Khandelwal N; Sialy R; Bhadada S
Indian J Med Res; 2010 Apr; 131():530-5. PubMed ID: 20424304
[TBL] [Abstract][Full Text] [Related]
20. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]